AAIC 2025 Abstract
Reanalysis of the A4 Study to Formally Evaluate Amyloid Removal as a Surrogate for Cognitive Decline
Trial in peopleInterventions
Abstract
Background: Amyloid removal has been used as surrogate outcomes in clinical trials of Alzheimer’s disease (AD) drugs, leading to approvals of aducanumab and lecanemab under the Accelerated Approval Program.
